Subscribe
eye-istock-489756064-mark_kuiken-
Mark_Kuiken / iStockphoto.com
20 March 2017Americas

Allergan to pay Editas $90m for development of CRISPR eye treatment

Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
CRISPR specialist raises $80m in funding
28 September 2018   US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.
Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
article
CRISPR specialist raises $80m in funding
28 September 2018   US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
article
CRISPR specialist raises $80m in funding
28 September 2018   US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York